Cantex Pharmaceuticals is a biopharmaceutical company developing medications to enhance the safety and effectiveness of existing cancer treatments.

Our lead product candidate, ODSH, is in advanced clinical development for acute myeloid leukemia, with the potential dual activity of accelerating full bone marrow recovery from intensive chemotherapy, while eliminating the leukemia stem cells that are responsible for disease resistance and recurrence.

Latest News


Cantex unveils advanced pipeline consisting of multiple Phase II ready programs. Clinical and regulatory milestones expected in 2014, 2015 and 2016.